
Invivyd, Inc. (IVVD) Stock Ticker
IVVD right now
Market factors today
Unlock the full IVVD picture
About Invivyd, Inc.
Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Adagio Therapeutics maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive antibodies. Furthermore, it partners with the Scripps Research Institute to conduct studies aimed at uncovering potential vaccine solutions for the prophylaxis, detection, or therapy of influenza or beta coronaviruses. Incorporated in 2020, the company's base of operations is in Waltham, Massachusetts.
IVVD stock facts
| Ticker symbol | IVVD |
| Exchange | NASDAQ Global Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $275.2M |
| CEO | Marc William Elia |
| Employees | 122 |
| Headquarters | New Haven, CT, US |
| IPO date | 2021-08-06 |
| Website | www.invivyd.com |
What you can see for IVVD on Tickr
Live IVVD price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the IVVD report.
Rankings
FAQ
What is the ticker symbol for Invivyd, Inc.?
The ticker symbol for Invivyd, Inc. is IVVD, listed on the NASDAQ Global Market.
What is IVVD?
Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management…